> V -2 strain ) (N=5 39; Zoster -091). The immune responses of the co -administered VACCINES were unaffected, with the exception of lower geometric mean concentrations (GMCs) for one of the pertussis antigens (pertactin) when Shi ngrix is co-administered with the d
> In adults aged 50 years and above, systemic adverse reactions that are very commonly reported (see Table 1 ; such as myalgia 32.9%, fatigue 32.2%, and headache 26.3% ), and arthralgia, uncommonly reported, following administration of SHINGRIX alone were reported with increased frequency when SHINGRIX was co- administered with a COVID -19 m
> Concomitant us e with OTHER VACCINES than those listed above  is not recommended due to lack of data .
